MA50441A - Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) - Google Patents
Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)Info
- Publication number
- MA50441A MA50441A MA050441A MA50441A MA50441A MA 50441 A MA50441 A MA 50441A MA 050441 A MA050441 A MA 050441A MA 50441 A MA50441 A MA 50441A MA 50441 A MA50441 A MA 50441A
- Authority
- MA
- Morocco
- Prior art keywords
- fibrosan
- pneumopathies
- ild
- treatment
- active agents
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 230000000750 progressive effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17197719 | 2017-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50441A true MA50441A (fr) | 2020-09-02 |
Family
ID=60162029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050441A MA50441A (fr) | 2017-10-23 | 2018-10-12 | Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11406638B2 (fr) |
| EP (1) | EP3700529A1 (fr) |
| JP (1) | JP7196169B2 (fr) |
| KR (1) | KR20200075864A (fr) |
| CN (1) | CN111278442B (fr) |
| AU (2) | AU2018357775B2 (fr) |
| BR (1) | BR112020003973A2 (fr) |
| CA (1) | CA3079299A1 (fr) |
| CL (1) | CL2020000627A1 (fr) |
| EA (1) | EA202090977A1 (fr) |
| IL (2) | IL309150A (fr) |
| MA (1) | MA50441A (fr) |
| MX (1) | MX2020004173A (fr) |
| PH (1) | PH12020550452A1 (fr) |
| TW (1) | TWI700088B (fr) |
| WO (1) | WO2019081235A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3180229A1 (fr) * | 2020-05-29 | 2021-12-02 | Cathy A. Swindlehurst | Biarylsulfonamides et compositions pharmaceutiques associees, et leur utilisation pour le traitement de maladies pulmonaires fibrotiques |
| CN113116904B (zh) * | 2021-03-23 | 2022-11-29 | 深圳市泰力生物医药有限公司 | 尼达尼布-甘草次酸复方制剂和药物复方制剂及在制备治疗肺纤维化药物中的应用 |
| WO2023104958A1 (fr) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | Nouvelle composition pharmaceutique orale et schéma posologique pour le traitement des pneumopathies interstitielles fibrosantes progressives |
| WO2023104961A1 (fr) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | Nouvelles combinaisons thérapeutiques pour le traitement de pneumopathies interstitielles fibrosantes progressives |
| WO2023235267A2 (fr) * | 2022-05-28 | 2023-12-07 | Avalyn Pharma Inc. | Compositions de poudre sèche de nintedanib et d'association de nintedanib et utilisations |
| TW202402289A (zh) * | 2022-06-02 | 2024-01-16 | 大陸商西藏海思科製藥有限公司 | Pde4b抑制劑及其用途 |
| TW202413371A (zh) * | 2022-06-16 | 2024-04-01 | 大陸商武漢人福創新藥物研發中心有限公司 | 作為pde4b抑制劑的含氮雜環類化合物 |
| WO2024032673A1 (fr) * | 2022-08-09 | 2024-02-15 | 西藏海思科制药有限公司 | Inhibiteur de pde4b et son utilisation |
| WO2024068386A1 (fr) | 2022-09-28 | 2024-04-04 | Boehringer Ingelheim International Gmbh | Utilisation de biomarqueurs dans le traitement d'états fibrotiques avec inhibiteur de la pde4b |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1049411A (fr) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | Pyridone n-substituee; methode generale de synthese des pyridones |
| PT706513E (pt) | 1993-07-02 | 2002-10-31 | Byk Gulden Lomberg Chem Fab | Benzimidazois substituidos por fluoralcoxi e sua utilizacao como inibidores de fosfodiesterase nucleotidica ciclica |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| DE102004057594A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057645A1 (de) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057618A1 (de) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057595A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2006111549A1 (fr) | 2005-04-21 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Dihydrothienopyrimidines destines au traitement de maladies inflammatoires |
| EP1847543A1 (fr) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidines pour le traitement de maladies inflammatoires |
| EP1870400A1 (fr) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Sels et sels cristallines d'un produit 2-indolinone |
| BRPI0817781A2 (pt) | 2007-10-19 | 2019-09-24 | Boehringer Ingelheim Int | piperazino-diidroteinopirimidinas substituídas com heterociclo |
| NZ585346A (en) | 2007-10-19 | 2011-09-30 | Boehringer Ingelheim Int | Substituted piperidino-dihydrothienopyrimidines |
| EA029996B1 (ru) | 2008-06-06 | 2018-06-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| US9802954B2 (en) * | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| WO2014124860A1 (fr) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Inhibiteurs spécifiques de pde4b pour le traitement du diabète sucré |
| CN106535896B (zh) * | 2015-04-27 | 2019-06-21 | 江苏恒瑞医药股份有限公司 | 蛋白激酶抑制剂在制备治疗纤维化疾病的药物中的用途 |
| CZ308695B6 (cs) * | 2015-07-29 | 2021-03-03 | Zentiva, K.S. | Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu) |
-
2018
- 2018-10-12 AU AU2018357775A patent/AU2018357775B2/en active Active
- 2018-10-12 KR KR1020207014628A patent/KR20200075864A/ko not_active Application Discontinuation
- 2018-10-12 MA MA050441A patent/MA50441A/fr unknown
- 2018-10-12 EA EA202090977A patent/EA202090977A1/ru unknown
- 2018-10-12 IL IL309150A patent/IL309150A/en unknown
- 2018-10-12 CN CN201880068509.6A patent/CN111278442B/zh active Active
- 2018-10-12 MX MX2020004173A patent/MX2020004173A/es unknown
- 2018-10-12 EP EP18785961.6A patent/EP3700529A1/fr active Pending
- 2018-10-12 WO PCT/EP2018/077952 patent/WO2019081235A1/fr unknown
- 2018-10-12 JP JP2020522715A patent/JP7196169B2/ja active Active
- 2018-10-12 IL IL273169A patent/IL273169B2/en unknown
- 2018-10-12 CA CA3079299A patent/CA3079299A1/fr active Pending
- 2018-10-12 BR BR112020003973-0A patent/BR112020003973A2/pt unknown
- 2018-10-22 US US16/166,239 patent/US11406638B2/en active Active
- 2018-10-22 TW TW107137119A patent/TWI700088B/zh active
-
2020
- 2020-03-11 CL CL2020000627A patent/CL2020000627A1/es unknown
- 2020-04-20 PH PH12020550452A patent/PH12020550452A1/en unknown
-
2022
- 2022-07-12 US US17/811,914 patent/US11813266B2/en active Active
-
2023
- 2023-06-29 US US18/343,792 patent/US20230405010A1/en active Pending
-
2024
- 2024-05-08 AU AU2024203045A patent/AU2024203045A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3079299A1 (fr) | 2019-05-02 |
| IL273169A (en) | 2020-04-30 |
| KR20200075864A (ko) | 2020-06-26 |
| JP2021500362A (ja) | 2021-01-07 |
| AU2018357775A1 (en) | 2020-03-19 |
| WO2019081235A1 (fr) | 2019-05-02 |
| EP3700529A1 (fr) | 2020-09-02 |
| AU2024203045A1 (en) | 2024-05-23 |
| TW201929858A (zh) | 2019-08-01 |
| JP7196169B2 (ja) | 2022-12-26 |
| IL273169B1 (en) | 2024-01-01 |
| US11813266B2 (en) | 2023-11-14 |
| US11406638B2 (en) | 2022-08-09 |
| EA202090977A1 (ru) | 2020-09-04 |
| US20190134043A1 (en) | 2019-05-09 |
| IL309150A (en) | 2024-02-01 |
| US20220378793A1 (en) | 2022-12-01 |
| IL273169B2 (en) | 2024-05-01 |
| CN111278442A (zh) | 2020-06-12 |
| CN111278442B (zh) | 2023-06-06 |
| TWI700088B (zh) | 2020-08-01 |
| US20230405010A1 (en) | 2023-12-21 |
| BR112020003973A2 (pt) | 2020-09-01 |
| MX2020004173A (es) | 2020-08-03 |
| AU2018357775B2 (en) | 2024-02-15 |
| CL2020000627A1 (es) | 2020-08-21 |
| PH12020550452A1 (en) | 2021-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50441A (fr) | Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| IL278178A (en) | Use of pilocarpine hydrochloride to treat eye disorder | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA41041A (fr) | Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii | |
| MA52253A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA53501A (fr) | Inhibiteurs de pde9 pour le traitement de la drépanocytose | |
| MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| MA55490A (fr) | Mutéine de lipocaline pour le traitement de l'asthme | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| MA41629A (fr) | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques | |
| FR3044227B1 (fr) | Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires |